Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07783347

Platelet-Rich Plasma Alone Versus PRP Plus Low-Intensity Shock Wave Therapy for Erectile Dysfunction

Erectile dysfunction is a common condition that may result from vascular, neurological, hormonal, psychological, or medication-related factors. Platelet-rich plasma (PRP) and low-intensity extracorporeal shock wave therapy (Li-ESWT) are regenerative treatment approaches that may improve erectile function through mechanisms involving angiogenesis, tissue repair, and improvement of penile vascular function.

This randomized prospective study will compare the efficacy and safety of PRP injection alone with combined PRP injection and Li-ESWT in men with erectile dysfunction. A total of 80 participants will be randomly assigned to two groups. One group will receive PRP injections alone, while the other group will receive PRP injections combined with Li-ESWT. Participants will be followed after treatment to assess changes in erectile function, erection hardness, penile blood flow, patient satisfaction, and treatment-related adverse events.

The study hypothesis is that adding Li-ESWT to PRP therapy will result in greater improvement in erectile function than PRP therapy alone.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Erectile Dysfunction Genital Diseases Genital Diseases, Male Male Urogenital Diseases Mental Disorders Sexual Dysfunction, Physiological Sexual Dysfunctions, Psychological Urogenital Diseases

Age range

30 year–65 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

Benha University Hospital

Banhā, Qalyubia Governorate, 13511, Egypt

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male participants aged 30-65 years.
  • Diagnosis of erectile dysfunction for at least 3 months.
  • Mild to moderate erectile dysfunction, defined by an International Index of Erectile Function-5 (IIEF-5) score of 8-21.
  • In a stable heterosexual relationship for at least 6 months.
  • Sexually active, with at least one sexual attempt per week.

Exclusion criteria

  • Severe erectile dysfunction, defined as IIEF-5 score <8.
  • Primary psychogenic erectile dysfunction based on clinical history with or without psychosexual assessment.
  • Anatomical penile abnormalities, including Peyronie's disease.
  • History of radical pelvic surgery or pelvic radiotherapy.
  • Uncontrolled diabetes mellitus, defined as HbA1c >9%.
  • Uncontrolled hypertension, defined as blood pressure >160/100 mmHg.
  • Recent myocardial infarction or stroke within the previous 6 months.
  • Unstable angina.
  • New York Heart Association class III-IV heart failure.
  • Severe hepatic impairment.
  • Severe renal impairment.
  • Hypogonadism, defined as total testosterone <300 ng/dL.
  • Hyperprolactinemia.
  • Untreated thyroid disease.
  • Current use of nitrates or nitric oxide donors.
  • Current use of alpha-blockers, unless the participant is on a stable low dose.
  • Current use of other phosphodiesterase type 5 inhibitors.

Treatment and study plan

Platelet-Rich Plasma

Biological

Autologous platelet-rich plasma will be prepared from approximately 20 mL of the participant's blood using a double-spin centrifugation method, targeting a platelet concentration of 3-5 times baseline. PRP will be administered by intracavernosal injection at two sites, with three injections given over 6 weeks at 2-week intervals.

Low-Intensity Extracorporeal Shock Wave Therapy

Device

Low-intensity extracorporeal shock wave therapy will be delivered to the penile shaft with or without treatment of the crura using an energy density of 0.15 mJ/mm² and 2,000 shocks per session. Participants will receive six sessions over 6 weeks, at a frequency of one session per week.

Primary outcomes

  1. Change From Baseline in International Index of Erectile Function-5 (IIEF-5) Score

    Time frame: Baseline and 4, 12, and 24 weeks after intervention

    Erectile function will be assessed using the International Index of Erectile Function-5 (IIEF-5), a 5-item self-administered questionnaire assessing erectile function and intercourse-related sexual performance. Each item is scored from 1 to 5, giving a total score ranging from 5 to 25, with higher scores indicating better erectile function. Scores are interpreted as: 22-25, no erectile dysfunction; 17-21, mild erectile dysfunction; 12-16, mild-to-moderate erectile dysfunction; 8-11, moderate erectile dysfunction; and 5-7, severe erectile dysfunction. Change from baseline in the total IIEF-5 score will be compared between the treatment groups.

  2. Change From Baseline in Erection Hardness Score (EHS)

    Time frame: Baseline and 4, 12, and 24 weeks after intervention

    Erection hardness will be assessed using the Erection Hardness Score (EHS), a single-item scale ranging from 0 to 4, with higher scores indicating greater erection rigidity. Scores are defined as follows: 0, penis does not enlarge; 1, penis is larger but not hard; 2, penis is hard but not hard enough for penetration; 3, penis is hard enough for penetration but not completely rigid; and 4, penis is completely hard and fully rigid. Change from baseline in the EHS will be compared between the treatment groups.

Secondary outcomes

  1. Change From Baseline in Penile Peak Systolic Velocity

    Time frame: Baseline and 4, 12, and 24 weeks after intervention

    Peak systolic velocity (PSV) will be measured using penile duplex Doppler ultrasonography to assess changes in penile arterial blood flow following treatment.

  2. Change From Baseline in Penile End-Diastolic Velocity

    Time frame: Baseline and 4, 12, and 24 weeks after intervention

    End-diastolic velocity (EDV) will be measured using penile duplex Doppler ultrasonography to assess changes in penile hemodynamics following treatment.

  3. Patient Satisfaction With Treatment

    Time frame: 4, 12, and 24 weeks after intervention

    Patient satisfaction with treatment will be assessed using a 5-point Likert scale. Participants will rate their overall satisfaction as: 1 = very dissatisfied, 2 = dissatisfied, 3 = neutral, 4 = satisfied, and 5 = very satisfied. Higher scores indicate greater treatment satisfaction. Satisfaction scores will be compared between the two treatment groups.

Interested in participating?

Not yet recruiting

Trial opening soon.

Get Notified

Sponsors and collaborators

Lead sponsor

Benha University

Other

Registry information

Official study title

Effect of Platelet-Rich Plasma Injection Alone Versus Combined Platelet-Rich Plasma and Low-Intensity Extracorporeal Shock Wave Therapy for the Treatment of Erectile Dysfunction

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Aug 24, 2026
Registry last updated
Aug 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.